BioCentury | Apr 6, 2015
Company News

University of Texas MD Anderson Cancer Center, Astellas deal

MD Anderson granted Astellas an option to license exclusive, worldwide rights to develop h8F4 after a Phase Ib trial to treat acute myelogenous leukemia (AML) conducted by MD Anderson. The compound is a preclinical humanized...
BioCentury | Apr 4, 2015
Company News

Astellas acquires option to MD Anderson's AML mAb

The University of Texas MD Anderson Cancer Center has granted Astellas Pharma Inc. (Tokyo:4503) an option to license exclusive, worldwide rights to h8F4 , an early stage antibody to treat acute myelogenous leukemia (AML). The molecule...
Items per page:
1 - 2 of 2